This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

BELLUS Health Croissance future

Future contrôle des critères 2/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for BELLUS Health.

Informations clés

46.1%

Taux de croissance des bénéfices

41.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	36.5%
Taux de croissance des recettes	69.0%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	16 Jun 2023

Mises à jour récentes de la croissance future

Recent updates

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Jan 16

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

Sep 07

Prévisions de croissance des bénéfices et des revenus

TSX:BLU - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2025	40	-147	-110	-64	3
12/31/2024	0	-141	-130	-127	3
12/31/2023	0	-117	-125	-101	2
3/31/2023	0	-87	-89	-89	N/A
12/31/2022	0	-76	-77	-77	N/A
9/30/2022	0	-73	-68	-68	N/A
6/30/2022	0	-71	-64	-64	N/A
3/31/2022	0	-70	-60	-60	N/A
12/31/2021	0	-71	-61	-61	N/A
9/30/2021	0	-64	-49	-49	N/A
6/30/2021	0	-47	-40	-40	N/A
3/31/2021	0	-37	-36	-36	N/A
12/31/2020	0	-32	-30	-30	N/A
9/30/2020	0	-34	-30	-30	N/A
6/30/2020	0	-35	-32	-32	N/A
3/31/2020	0	-33	-29	-29	N/A
12/31/2019	0	-26	-21	-21	N/A
9/30/2019	0	-18	-14	-14	N/A
6/30/2019	0	-14	-9	-9	N/A
3/31/2019	0	-9	-8	-8	N/A
12/31/2018	0	-7	-7	-7	N/A
9/30/2018	0	-6	-7	-7	N/A
6/30/2018	0	-5	-6	-6	N/A
3/31/2018	0	-4	-5	-5	N/A
12/31/2017	0	-1	-5	-3	N/A
9/30/2017	0	-1	-4	-3	N/A
6/30/2017	1	0	-3	-2	N/A
3/31/2017	1	0	-3	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	3	-1	N/A	-2	N/A
6/30/2016	3	0	N/A	-2	N/A
3/31/2016	3	0	N/A	-2	N/A
12/31/2015	3	0	N/A	-2	N/A
9/30/2015	2	0	N/A	-2	N/A
6/30/2015	2	-1	N/A	-2	N/A
3/31/2015	2	-1	N/A	-2	N/A
12/31/2014	2	-2	N/A	-3	N/A
9/30/2014	2	-2	N/A	-3	N/A
6/30/2014	2	-1	N/A	-4	N/A
3/31/2014	2	-1	N/A	-3	N/A
12/31/2013	2	-1	N/A	-3	N/A
9/30/2013	2	-1	N/A	-3	N/A
6/30/2013	2	-2	N/A	-3	N/A
3/31/2013	2	-10	N/A	-3	N/A
12/31/2012	2	-13	N/A	-3	N/A
9/30/2012	3	-15	N/A	-2	N/A
6/30/2012	3	-14	N/A	-2	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BLU is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: BLU is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: BLU is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: BLU's revenue (69% per year) is forecast to grow faster than the Canadian market (5.3% per year).

Croissance élevée des revenus: BLU's revenue (69% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if BLU's Return on Equity is forecast to be high in 3 years time

This company has been acquired

BELLUS Health Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 40%, EPS downgraded

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Consensus revenue estimates fall by 93%

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

Recent updates

BELLUS Health Inc.(NasdaqGS:BLU) dropped from NASDAQ Composite Index

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

President exercised options to buy CA$35m worth of stock.

Consensus revenue estimates increase by 40%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 22%, EPS upgraded

Price target decreased by 30% to CA$14.75

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans

Insufficient new directors

Independent Lead Director recently sold CA$449k worth of stock

President exercised options and sold CA$3.1m worth of stock

Independent Director recently sold CA$433k worth of stock

Consensus revenue estimates fall by 93%

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation

First half 2022 earnings released

BELLUS Health Inc. Expects to Initiate A Phase 1 Clinical Trial Investigating A Once-Daily, Extended-Release Formulation of BLU-5937 in the Fourth Quarter of 2022

Bellus Health Inc. Announces Positive End-Of-Phase 2 Meeting with the FDA and Its Calm Phase 3 Program for BLU-5937 in Refractory Chronic Cough

Price target increased to CA$18.50

Consensus revenue estimates increase by 56%

We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely

Senior Vice President of Finance recently sold CA$576k worth of stock

Chief Scientific Officer recently sold CA$951k worth of stock

BELLUS Health Inc., Annual General Meeting, May 11, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Consensus forecasts updated

Consensus revenue estimates increase by 16%

Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation

Bellus Health Announces Positive Topline Results from Its Phase 2B Soothe Trial of Blu-5937 for the Treatment of Refractory Chronic Cough

Price target increased to CA$16.40

Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.094 loss in 3Q 2020)

BELLUS Health Inc. Announces Completion of Patient Enrollment in Soothe Phase 2B Trial for Refractory Chronic Cough and Blueprint Phase 2A Trial for Chronic Pruritus Associated with Atopic Dermatitisz

BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough

Price target increased to CA$10.70

Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance